Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients

Overview

To evaluate the effect of oral Phytoestrogen or Isosorbid mononitrate or N-acetyl cysteine as an adjuvant to clomiphene citrate on induction of ovulation and pregnancy outcomes in patients with PCOS. In this three-arm open RCT, 240 PCOS infertile women were randomly divided to 3 groups for induction of ovulation. Group A, [PE group, n= 80] patients received CC 100mg/d plus oral Phytoestrogen120 mg/ day and patients in Group B, [ISMN group, n=80] received CC 100 mg/d plus 20 mg Isosorbid mononitrate and Group C, [NAC group, n=80] patients received CC 100 mg/d plus NAC 1200 mg/day.

Full Title of Study: “Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: December 2015

Interventions

  • Drug: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine

Arms, Groups and Cohorts

  • Active Comparator: Phytoestrogen
    • Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
  • Active Comparator: Isosorbid mononitrate
    • Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
  • Active Comparator: N-Acetyl cysteine
    • Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.

Clinical Trial Outcome Measures

Primary Measures

  • clinical pregnancy rate
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

1. All patients have PCOS. 2. All patients received CC 100 mg/day for 5 days starting from day 5 with successful ovulation as documented by folliculometry and midluteal serum progesterone with no pregnancy achieved. 3. All patients have patent fallopian tubes by Hysterosalpingography. 4. Their husbands have normal semen analysis according to the modified criteria of WHO. 5. All patients have normal serum prolactin and thyroid profile. 6. Any patient having vaginitis was treated before starting induction. Exclusion Criteria:

1. Other causes of infertility than anovulation. 2. Diabetes or other endocrinological disorders. 3. Age > 40 years. 4. Smoking. 5. Alcohol use. 6. Presence of ovarian cyst >2cm on the second day of the cycle. 7. Patients who have received gonadotrophins in the preceeding 6 months. 8. Patients who have done unilateral or bilateral ovarian drilling. 9. Allergy to PE, NO donors or NAC

Gender Eligibility: Female

Minimum Age: 20 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kasr El Aini Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Nawara Mohamed Hashish, Assistant professor – Kasr El Aini Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.